The Congenital and Perinatal Infections Consortium (CPIC) brings together a group of 28 study sites that have a longstanding history of research in pediatric infectious diseases with community and industry stakeholders. Its overall goal is to establish infrastructure and institutional cooperation — focusing on rare congenital and perinatal viral infections — to advance understanding of these diseases, train future researchers, improve clinical trial readiness, test therapies, advance patient care, and ultimately reduce disease burden. These infections include congenital cytomegalovirus (CMV) disease, neonatal herpes simplex virus (HSV) infection, and neonatal viral sepsis caused by enteroviruses (EVs) and the related human parechoviruses (HPeVs).

Led by researchers at the University of Alabama at Birmingham (UAB) and supported by an experienced and highly efficient study team, the 28 study sites that comprise the CPIC have cooperated closely for decades as the Collaborative Antiviral Study Group (CASG) to investigate the natural history and treatment of rare congenital and perinatal infectious diseases. These longstanding relationships, as well as partnerships with community and industry stakeholders, will facilitate the success of our research efforts and our mentored career enhancement activities. As with all successful research programs, answers to critical questions always lead to identification of the next important questions that will further advance the field. These questions are the basis of the CPIC research portfolio that will advance the care of children with rare neonatal viral infections and provide experiential mentored research opportunities as we train the future generation of rare diseases researchers.

CPIC is funded by the National Institute for Allergy and Infectious Diseases (NIAID) and the National Center for Advancing Translational Science (NCATS).


  1. Build upon clinical research advances achieved by the CASG to further advance the diagnosis, treatment, and understanding of HSV, CMV, and EV in the neonatal population.
  2. Leverage longstanding relationships with study sites and stakeholders to conduct high-quality clinical research projects .
  3. Advance rare diseases research by sharing standardized data and access to core capacities.
  4. Develop and utilize pilot and feasibility funding to advance science related to rare infectious diseases impacting neonates.
  5. Support mentored research and career enhancement opportunities for clinical fellows and junior faculty to facilitate the development of early-stage investigators in rare diseases research.

Diseases Studied

  • Congenital cytomegalovirus (CMV) infection
  • Neonatal herpes simplex virus (HSV) infection
  • Perinatal enterovirus (EV) infection
  • Perinatal parechovirus infection

Active Studies

  • A Longitudinal Study of the Durability of Valganciclovir Therapy on Long-Term Hearing and Neurodevelopmental Outcomes in Adolescents Treated During Infancy for Symptomatic Congenital Cytomegalovirus Diseases
  • Neonatal Enterovirus and Human Parechovirus Viral Sepsis: Natural History and Predictors of Morbidity and Mortality
  • A Phase I Adaptive, Multiple Dose Pharmacokinetic and Safety Assessment of Valacyclovir in Infants At Risk of Acquiring Neonatal Herpes Simplex Virus Disease
  • A Phase I, Adaptive, Escalating Single-Dose and Multiple-Dose Pharmacokinetic and Safety Assessment of Letermovir in Infants With Symptomatic Congenital Cytomegalovirus Disease